^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-06263507

    i
    Other names: PF-06263507
    Company:
    Pfizer
    Drug class:
    Microtubule inhibitor, 5T4-targeted antibody-drug conjugate
    Related drugs:
    over3years
    ASN004, a 5T4-targeting scFv-Fc antibody-drug conjugate with high drug-to-antibody ratio, induces complete and durable tumor regressions in preclinical models. (PubMed, Mol Cancer Ther)
    In head-to-head studies, superior activity of ASN004 was demonstrated against trastuzumab-DM1, in a low-5T4/high-HER2 expressing gastric tumor model, and 10-fold greater potency was found for ASN004 against the 5T4-targeted ADC PF-06263507 in a lung tumor model. In marmoset monkeys, ASN004 was well tolerated at doses up to 1.5 mg/kg Q3W iv, and showed dose-dependent exposure, linear pharmacokinetics, and markedly low exposure of free payload drug. Taken together, these findings identify ASN004 as a promising new ADC therapeutic for clinical evaluation in a broad range of solid tumor types.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 expression • HER-2-H
    |
    Kadcyla (ado-trastuzumab emtansine) • ASN004 • PF-06263507